Cutler Group LP Rigel Pharmaceuticals Inc Transaction History

Cutler Group LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$0.67 - $3.19 $67 - $319	-100 Reduced 7.69%	1,200 $1,000
Q1 2022 Apr 14, 2022	BUY	$2.22 - $3.45 $222 - $345	100 Added 8.33%	1,300 $3,000
Q3 2021 Oct 26, 2021	SELL	$3.5 - $4.5 $5,260 - $6,763	-1,503 Reduced 55.6%	1,200 $4,000
Q2 2021 Jul 19, 2021	BUY	$3.09 - $4.54 $4,644 - $6,823	1,503 Added 125.25%	2,703 $11,000
Q1 2021 Apr 26, 2021	SELL	$3.35 - $4.93 $25,667 - $37,773	-7,662 Reduced 86.46%	1,200 $4,000
Q4 2020 Jan 21, 2021	BUY	$2.35 - $3.74 $18,005 - $28,655	7,662 Added 638.5%	8,862 $31,000
Q3 2020 Oct 27, 2020	BUY	$1.78 - $4.13 $2,136 - $4,956	1,200 New	1,200 $2,000
Q2 2019 Aug 09, 2019	SELL	$2.02 - $2.61 $3,434 - $4,437	-1,700 Closed	0 $0
Q1 2019 May 10, 2019	SELL	$2.0 - $2.65 $600 - $795	-300 Reduced 15.0%	1,700 $4,000
Q3 2018 Nov 07, 2018	BUY	$2.6 - $3.59 $5,200 - $7,180	2,000 New	2,000 $6,000
Q2 2018 Aug 10, 2018	SELL	$2.83 - $4.11 $14,999 - $21,783	-5,300 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$3.54 - $4.54 $18,762 - $24,062	5,300 New	5,300 $18,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.84B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.